US-based Purdue Pharma, makers of painkiller OxyContin agreed to pay $600 million in fines and other payments to resolve the criminal charge of misbranding the product , one of the largest amounts ever paid by a drug company in such a case.
Three of its current and former executives pleaded guilty Thursday to criminal charges that it had misled doctors and patients when it claimed the drug was less likely to be abused than traditional narcotics.
The three executives, including its president and its top lawyer, also pleaded guilty to misdemeanor charges of misbranding the drug. Together, they agreed to pay $34.5 million in fines.
The hearing included statements by numerous people who said their lives were changed forever by the addiction potential of OxyContin, a trade name for a long-acting form of the painkiller oxycodone.
OxyContin is a powerful, long-acting narcotic that provides relief of serious pain for up to 12 hours.
Initially, Purdue Pharma contended that OxyContin, because of its time-release formulation, posed a lower threat of abuse and addiction to patients than traditional, faster-acting painkillers like Percocet or Vicodin.
That claim became the linchpin of an aggressive marketing campaign that helped the company sell over $1 billion worth of OxyContin a year.
Purdue Pharma, based in Stamford, Connecticut, heavily promoted OxyContin to doctors like general practitioners, who often had little training in treating serious pain or in recognizing signs of drug abuse.
But experienced drug abusers and novices, including teenagers, soon discovered that chewing an OxyContin tablet or crushing one and then snorting the powder, or injecting it with a needle produced a high as powerful as heroin.
OxyContin is a pure, high-strength version of a long-used narcotic, oxycodone. By 2000, parts of the United States, particularly rural areas, began to see soaring raPage: 1 2 3 4 Related medicine news :1
. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries2
. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries3
. Pharma cos must forge Strategic alliances4
. Medicis Pharmaceutical company enters pediatric market 5
. Pharma majors gear to supply anti-anthrax drug 6
. Pharmacies in for a dose of bitter medicine7
. Andhra Pradesh to set up Pharma City8
. Sun Pharma to launch chiral version of omeprazole soon 9
. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories 10
. Pharmacia may take 51.5 percent Abbott stake 11
. Pharmaceutical companies are targeting patients